抗合成酶综合征与恶性肿瘤关联的系统综述与荟萃分析
I2=70%)。年龄较大(P=0.018)与随访时间较长(P=0.013)与恶性肿瘤显著相关,而抗Jo-1阳性及其他临床表现未见显著关联。作者认为ASyS总体恶性肿瘤风险较低,筛查应按年龄和性别个体化制定。
要点
- 成人ASyS合并恶性肿瘤患病率为8.3%(95%CI 7.5-9.1%),总体风险偏低。
- 年龄较大与随访时间较长与恶性肿瘤风险显著相关(P分别为0.018与0.013)。
- 抗Jo-1阳性及ASyS其他临床表现与恶性肿瘤无显著关联。
核心结论
- ASyS总体恶性肿瘤风险似乎较低,年龄和随访时间与较高风险相关,临床表现则无关。
- 不同抗体亚型间恶性肿瘤率存在数值差异(抗Jo-1为6.4%至抗OJ为13.3%),但无统计学 significance。
研究设计与样本
- 遵循PRISMA指南与PROSPERO方案(CRD42024540200)的系统综述与荟萃分析。
- 检索PubMed、Embase、Web of Science核心合集、Scopus与CENTRAL,纳入报告成人ASyS患者恶性肿瘤的研究。
- 采用改良Newcastle-Ottawa量表评估偏倚风险,采用GRADE评估证据确定性。
主要发现
- 合并恶性肿瘤患病率为8.3%(95%CI 7.5-9.1%;I2=70%)。
- 年龄较大(P=0.018)和随访时间较长(P=0.013)与恶性肿瘤显著相关。
- 抗Jo-1阳性或其他ASyS临床表现与恶性肿瘤未见显著关联。
- 各抗体亚型恶性肿瘤患病率数值上不同(抗Jo-1为6.4%至抗OJ为13.3%),但无统计学 significance。
- 乳腺癌、肺癌与结肠癌被频繁报告。
关键数值与推荐
- 合并恶性肿瘤患病率8.3%(95%CI 7.5-9.1%;I2=70%)。
- 年龄与随访时间与恶性肿瘤的关联P值分别为0.018与0.013。
- 抗Jo-1为6.4%、抗OJ为13.3%的亚型患病率数值,未达统计学 significance。
临床怎么用
- 临床可参考ASyS总体恶性肿瘤风险较低的估计,避免对所有患者统一强化肿瘤筛查。
- 对年龄较大或随访时间较长的ASyS患者应关注恶性肿瘤风险。
- 癌症筛查应按患者年龄和性别进行个体化制定。
局限性
- 合并患病率存在中度异质性(I2=70%)。
- 抗体亚型间差异无统计学 significance,相关比较需谨慎解读。
- 原文摘要未报告偏倚风险与GRADE证据确定性的具体评级结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Anti-synthetase syndrome (ASyS) is a rare autoimmune disorder defined by anti-synthetase antibodies. While malignancy is established in DM, its association with ASyS remains unclear. We aimed to estimate malignancy prevalence in ASyS and assess whether autoantibody subtype, age, sex or clinical features influence malignancy risk. METHODS: We performed a systematic review and meta-analysis following PRISMA guidelines and a PROSPERO protocol (CRD42024540200). PubMed, Embase, Web of Science Core Collection, Scopus and CENTRAL were searched for studies reporting malignancy in adult ASyS patients. A random intercept logistic regression model estimated pooled prevalence and enabled meta-regression. Risk of bias was assessed with a modified Newcastle-Ottawa Scale, and certainty of evidence with GRADE. RESULTS: Forty-three studies including 4451 patients were eligible. The pooled malignancy prevalence was 8.3% (95% CI 7.5-9.1%; I2 = 70%). Older age (P = 0.018) and longer follow-up (P = 0.013) were significantly associated with malignancy. No significant associations were found with anti-Jo-1 positivity or other clinical manifestations of ASyS. Malignancy prevalence numerically varied across antibody subtypes (6.4% anti-Jo-1 to 13.3% anti-OJ). Breast, lung and colon cancer were frequently reported. CONCLUSION: The overall malignancy risk in ASyS appears low. Age and length of follow-up were associated with higher malignancy risk, whereas clinical manifestations were not. Although the malignancy rates differed between antibody subtypes, with the numerically highest prevalence in anti-OJ antibodies, these findings were not statistically significant. Since the risk of malignancy in the ASyS population appears to be low in general, cancer screening should be tailored according to the patients age and sex.
引用
- Leemans E, De Haes P, Lenaerts J, et al. Association between anti-synthetase syndrome and malignancy: a systematic review and meta-analysis. Rheumatology (Oxford). 2026. PMID: 41761500. doi:10.1093/rheumatology/keag110
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。